Anavex Life Sciences (AVXL) Long-Term Deferred Tax (2015 - 2025)
Anavex Life Sciences (AVXL) posted Long-Term Deferred Tax of $54.8 million for Q3 2025, up 262.6% sequentially from $15.1 million in Q3 2024, and up 262.6% YoY from $15.1 million in Q3 2024.
Anavex Life Sciences (AVXL) Long-Term Deferred Tax (2015 - 2025) Analysis & Trends
Anavex Life Sciences has reported Long-Term Deferred Tax for 11 years, with the latest figure at $54.8 million in Q3 2025.
- Quarterly Long-Term Deferred Tax rose 262.6% year-over-year to $54.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $54.8 million (up 262.6% YoY) and the FY2025 annual result came in at $54.8 million, up 262.6% from the prior year.
- Long-Term Deferred Tax improved to $54.8 million in Q3 2025 per AVXL's latest filing, from $15.1 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $54.8 million in Q3 2025 and troughed at $15.1 million in Q3 2024.
- A 5-year average of $39.5 million and a median of $46.2 million in 2022 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax plunged 67.5% in 2024, then soared 262.6% in 2025.
- Over 5 years, Long-Term Deferred Tax stood at $35.0 million in 2021, then jumped by 32.09% to $46.2 million in 2022, then gained by 0.55% to $46.5 million in 2023, then sank by 67.5% to $15.1 million in 2024, then jumped by 262.6% to $54.8 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $54.8 million, $15.1 million, and $46.5 million for Q3 2025, Q3 2024, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 54.75 Mn |
| Sep 30, 2024 | 15.10 Mn |
| Sep 30, 2023 | 46.46 Mn |
| Sep 30, 2022 | 46.21 Mn |
| Sep 30, 2021 | 34.98 Mn |
| Sep 30, 2020 | 23.40 Mn |
| Sep 30, 2019 | 18.70 Mn |
| Jun 30, 2019 | 151,133.00 |
| Sep 30, 2018 | 13.56 Mn |
| Sep 30, 2017 | 14.24 Mn |
| Sep 30, 2016 | 11.22 Mn |
| Sep 30, 2015 | 9.18 Mn |